For research use only. Not for therapeutic Use.
Ravagalimab (ABBV-323) is a CD40 antagonist (EC50: 3.7 nM). Ravagalimab can be used for research of Crohn’s disease[1].
Ravagalimab (0-100 nM, 2 days) inhibits CD86 upregulation on primary human B cells with an EC50 of 0.6 nM[2].
| Catalog Number | I041539 |
| CAS Number | 2050816-56-1 |
| Purity | ≥95% |
| Reference | [1]. Argiriadi MA, et al. CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Mol Cell Biol. 2019 Aug 5;20(1):29. [2]. Yu X, et al. Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity. Cancer Cell. 2020 Jun 8;37(6):850-866.e7. |
